Ignite Creation Date:
2024-05-05 @ 6:52 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00551798
Status:
COMPLETED
Last Update Posted:
2011-05-17
First Post:
2007-10-30
Brief Title:
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkins Disease and Lymphoma Malins High Grade
Sponsor:
University Hospital Limoges
Organization:
University Hospital Limoges
Study Overview
Official Title:
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkins Disease and Lymphoma Malins High Grade
Status:
COMPLETED
Status Verified Date:
2005-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MIBI
Brief Summary:
Predicting response to chemotherapy in patients with Hodgkins disease or lymphoma high-grade malignant de novo or recurrence
The non-Hodgkins lymphoma and high-grade Hodgkins disease may show resistance to chemotherapy regardless of their initial extension The failure of treatment is most often correlated with an incomplete answer or lack of response to chemotherapy as a result chemoresistance This drug which may involve the gene MDR1 multidrug resistance encoding the protein PGP can be studied in vivo by MIBI scan The MIBI is behind a tracer perfusionnel used routinely to explore myocardial perfusion but it has other characteristics of fixing which can be used in oncological imaging fixation by glial tumors of high gradeProspective Study which includes conducting a tomoscintigraphie 30 minutes after injection of 20 mCi of 99mTc-MIBI in initial stock or relapse of high-grade lymphoma and Hodgkins disease any stage I-IV Fixing the MIBI is compared with morphological abnormalities detected by CT and the setting of lesions by 18FDG Patients will be treated in a traditional way without changes in treatment protocols used in routine Patients with a negative MIBI scan will be watched with particular attention in order to detect insufficient response to chemotherapy The only change the care of patients only for the achievement of an initial consideration of non-invasive imaging further which is the tomoscintigraphie the MIBI Of the tumor samples will be evaluated by immunohistochemistry the expression of PGP and the MRP1 two proteins associated with the drug On blood may be carried out genotyping of MDR1 MRP1 and MRP2 to the patient
The non-Hodgkins lymphoma and high-grade Hodgkins disease may show resistance to chemotherapy regardless of their initial extension The failure of treatment is most often correlated with an incomplete answer or lack of response to chemotherapy as a result chemoresistance This drug which may involve the gene MDR1 multidrug resistance encoding the protein PGP can be studied in vivo by MIBI scan The MIBI is behind a tracer perfusionnel used routinely to explore myocardial perfusion but it has other characteristics of fixing which can be used in oncological imaging fixation by glial tumors of high gradeProspective Study which includes conducting a tomoscintigraphie 30 minutes after injection of 20 mCi of 99mTc-MIBI in initial stock or relapse of high-grade lymphoma and Hodgkins disease any stage I-IV Fixing the MIBI is compared with morphological abnormalities detected by CT and the setting of lesions by 18FDG Patients will be treated in a traditional way without changes in treatment protocols used in routine Patients with a negative MIBI scan will be watched with particular attention in order to detect insufficient response to chemotherapy The only change the care of patients only for the achievement of an initial consideration of non-invasive imaging further which is the tomoscintigraphie the MIBI Of the tumor samples will be evaluated by immunohistochemistry the expression of PGP and the MRP1 two proteins associated with the drug On blood may be carried out genotyping of MDR1 MRP1 and MRP2 to the patient
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None